Stifel Financial
CRSP icon

Stifel Financial’s CRISPR Therapeutics CRSP Stock Holding History

Stifel Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.82M Sell
38,183
-13,997
-27% -$738K ﹤0.01% 2038
2025
Q4 		$2.74M Buy
52,180
+13,630
+35% +$816K ﹤0.01% 1721
2025
Q3 		$2.5M Sell
38,550
-4,400
-10% -$253K ﹤0.01% 1760
2025
Q2 		$2.09M Buy
42,950
+3,931
+10% +$152K ﹤0.01% 1828
2025
Q1 		$1.33M Sell
39,019
-4,109
-10% -$174K ﹤0.01% 2045
2024
Q4 		$1.7M Buy
43,128
+2,891
+7% +$137K ﹤0.01% 1895
2024
Q3 		$1.89M Sell
40,237
-10,175
-20% -$516K ﹤0.01% 1813
2024
Q2 		$2.72M Sell
50,412
-9,020
-15% -$522K ﹤0.01% 1513
2024
Q1 		$4.05M Buy
59,432
+4,580
+8% +$328K ﹤0.01% 1269
2023
Q4 		$3.43M Buy
54,852
+27,973
+104% +$1.55M ﹤0.01% 1321
2023
Q3 		$1.22M Sell
26,879
-1,982
-7% -$102K ﹤0.01% 1910
2023
Q2 		$1.62M Sell
28,861
-682
-2% -$38.7K ﹤0.01% 1773
2023
Q1 		$1.34M Sell
29,543
-420
-1% -$20.4K ﹤0.01% 1837
2022
Q4 		$1.22M Buy
29,963
+797
+3% +$42.3K ﹤0.01% 1853
2022
Q3 		$1.91M Buy
29,166
+6,070
+26% +$440K ﹤0.01% 1513
2022
Q2 		$1.4M Sell
23,096
-10,529
-31% -$619K ﹤0.01% 1747
2022
Q1 		$2.11M Buy
33,625
+4,234
+14% +$266K ﹤0.01% 1579
2021
Q4 		$2.23M Sell
29,391
-6,031
-17% -$527K ﹤0.01% 1532
2021
Q3 		$3.96M Buy
35,422
+13,004
+58% +$1.63M 0.01% 1151
2021
Q2 		$3.63M Sell
22,418
-72
-0.3% -$8.76K 0.01% 1203
2021
Q1 		$2.74M Buy
22,490
+5,689
+34% +$859K ﹤0.01% 1325
2020
Q4 		$2.57M Buy
16,801
+4,166
+33% +$492K ﹤0.01% 1237
2020
Q3 		$1.06M Buy
12,635
+742
+6% +$65.8K ﹤0.01% 1589
2020
Q2 		$874K Sell
11,893
-388
-3% -$22.7K ﹤0.01% 1659
2020
Q1 		$522K Buy
12,281
+719
+6% +$37.1K ﹤0.01% 1838
2019
Q4 		$705K Buy
11,562
+1,767
+18% +$96.5K ﹤0.01% 2050
2019
Q3 		$400K Buy
9,795
+1,491
+18% +$71.2K ﹤0.01% 2283
2019
Q2 		$399K Buy
+8,304
New +$332K ﹤0.01% 2323

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Stifel Financial's CRSP Position: Q1 2026 in Review

Stifel Financial reduced its CRISPR Therapeutics (CRSP) stake by 27% in Q1 2026, selling an estimated $738K and leaving 38,183 shares worth $1.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2038.

Stifel Financial first reported a position in CRSP in Q2 2019 and has held it in 28 quarters since. The position peaked at $4.05M in Q1 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Stifel Financial held 38,183 shares of CRISPR Therapeutics worth $1.82M as of Q1 2026.
  • Stifel Financial sold 13,997 CRISPR Therapeutics shares in Q1 2026, an estimated $738K.
  • CRISPR Therapeutics made up ﹤0.01% of Stifel Financial's portfolio in Q1 2026, its #2038 holding.
  • Stifel Financial first reported a position in CRISPR Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Stifel Financial's CRISPR Therapeutics position peaked at $4.05M in Q1 2024.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Stifel Financial's 13F filing for Q1 2026, filed 12 May 2026.